Vibha A. Szafron, MD
Assistant Professor, Division of Immunology, Allergy, and Retrovirology, Baylor College of Medicine
Languages: English
Get to know Vibha A. Szafron, MD
Personal Statement
Dr. Szafron strives to advocate for and improve the quality of life of all patients living with allergic and immunologic diseases. She practices evidence-based medicine with a primary clinical focus on the diagnosis and treatment of food allergies, eczema, asthma, allergic rhinitis, drug allergies and urticaria (hives). In addition, she is motivated to provide meaningful education to her patients, their families and the allergy community.
Dr. Szafron’s specific interest is the prevention of food allergy in young children as early childhood is a vital time to collaborate with and help families successfully introduce foods while guiding treatment of food allergy. Her current research focuses on studying the immune factors in breast milk and their impact on prevention or development of food allergy.
Clinical Interests:
Food allergy, eczema, allergic rhinitis, asthma, drug allergy
Research Interests:
Prevention of food allergy
Breastfeeding and food allergy
Quality of life
Medical education and community education
Education
,
,
,
Organizations
,
,
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Szafron V, Anvari S, Pickett G, Staggers KA, Minard CG, Rogers J, Washington A, Davis CM. Assessing health-related quality of life in children with food allergy and eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2021 Jun;9(6):2520-2523.e2.
Szafron V, Anagnostou A. Management of Anaphylaxis During Peanut Oral Immunotherapy. Curr Allergy Asthma Rep. 2023 Jan;23(1):21-27.
Koo G, Anvari S, Friedman DL, Zarnegar-Lumley S, Szafron V, Kahwash BM, Onasch KM, Hall L, Phillips EJ, Stone CA Jr. mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase. J Allergy Clin Immunol Pract. 2022 Jan;10(1):322-325.